This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
This Article supports Sustainable Development Goal 3 by highlighting differential effects of sleep disturbances on resting-state neural activity in patients on the Alzheimer's disease spectrum relative to healthy adults, suggesting a key role of sleep disturbances in the neurophysiological changes seen in Alzheimer's disease, with implications for basic research and clinical intervention.
This Article supports Sustainable Development Goal 3 by describing a cohort characterization model for Alzheimer’s Disease built on medications and diagnoses data that are widely available in a structured format in electronic health records (EHRs), showing that standard machine learning applied to sequences of EHR data can produce scalable computational characterization of Alzheimer’s disease cohorts.
This Article supports Sustainable Development Goal 3 by estimating the proportion of dementia attributable to hypertension, finding an overall global population attributable fraction of 15.8%. Results were also broken down by region and age. The authors note that the estimates from this study could help to inform public health policy at global and national levels.
This Comment article supports SDG 3 and 16 by highlighting how complex humanitarian settings have become fertile environments for spreading misinformation, disinformation, and malinformation, and how the 2021 release of the Oxford Statement on International Law Protection in Cyberspace, which touches on sovereignty, incitement, human rights, criminal law, general rules of international humanitarian law, and international criminal law, is an important first step to address this type of disinformation.
Elsevier,
Overcoming Obstacles in Drug Discovery and Development, Surmounting the Insurmountable—Case Studies for Critical Thinking 2023
Racial and ethnic disparities among clinical trial participants is a long-standing issue demanding attention in the research community as advances in precision medicine increase. This exclusion from clinical trial enrollment has tangible consequences, preventing traditionally underserved populations from benefitting from health innovation and cutting-edge technologies. Aggregation of populations into a generalized treatment population lends to the evident healthcare inequities we see today and support SDG3
This News item supports SDG 3 by describing the work of the PAHO Commission on Mental Health and COVID-19, which was created in order to improve mental health care in the Latin America and Caribbean region in light of the mental health crisis resulting from the pandemic. The article describes the 10 recommendations set forth by the Commission, and the opportunities and implications of these recommendations.
This Article supports SDG 3 by evaluating alanine transaminase antiviral treatments for hepatitis B virus infection in China. The authors suggest the optimal treatment coverage for both cost-effectiveness and mortality reduction based on their findings
This Article supports SDG 3 by evaluating shared-care models with hepatitis B virus testing in China, including an analysis of the cost-effectiveness and the impact on quality of life and mortality.
This Review supports SDG 3 by assessing the availablility of data for reporting elimination targets of mother-to-child transmission of HIV, hepatitis B, and syphilis, and reports on progress towards these targets in Pacific Island countries and territories.
